{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:41:50Z","timestamp":1761129710424,"version":"3.37.3"},"reference-count":10,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["Unrestricted Grant ('Gilead Sciences BeLux Fellows"],"award-info":[{"award-number":["Unrestricted Grant ('Gilead Sciences BeLux Fellows"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2019,12,12]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>\nRecent evidence shows that patients using HIV pre-exposure prophylaxis (PrEP) have an increased rate of bacterial STIs, including syphilis, chlamydia and gonorrhoea. Our study aimed to describe the acquisition and the susceptibility for macrolides of\n<jats:italic>Mycoplasma genitalium<\/jats:italic>\nin men who have sex with men (MSM) on PrEP.\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>\nWe studied all MSM who started PrEP in the AZ Sint-Jan Hospital Bruges from 1 June 2017 to 31 March 2019 with at least one follow-up visit. Patients were screened for\n<jats:italic>M. genitalium<\/jats:italic>\nand other STIs with pooled rectal swabs, pharyngeal swabs and first-voided urine, and blood samples at baseline and quarterly intervals after initiating PrEP. TaqMan Array Card technology was used to detect\n<jats:italic>M. genitalium<\/jats:italic>\nand determine macrolide-resistance mediating mutations in region V of the 23S rRNA gene (A2058G, A2059G, A2058C and others). Patients with an STI were treated based on a national guideline.\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>\n131 MSM (median age 40 years, range 20\u201379) were included in the study. The median follow-up time was 12 months (IQR 6.1\u201317). Baseline prevalence of\n<jats:italic>M. genitalium<\/jats:italic>\nwas 6.9% and incidence rate after PrEP initiation was 28.8 per 100 person-years (95%\u2009CI 21.7 to 37.2), without significant differences in proportions between the first four quarterly intervals. All but one acquisitions were asymptomatic. Younger age and positivity for\n<jats:italic>M. genitalium<\/jats:italic>\nat baseline were significantly associated with incident\n<jats:italic>M. genitalium<\/jats:italic>\nacquisition. The observed proportion of macrolide resistance increased not significantly from 44% at baseline to 57%\u201386% after PrEP initiation. None of the 27 macrolide-resistant\n<jats:italic>M. genitalium<\/jats:italic>\nacquisitions could be linked to azithromycin exposure in the three preceding months.\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>\nAfter initiation of PrEP, we found a stable incidence of almost exclusively asymptomatic\n<jats:italic>M. genitalium<\/jats:italic>\n. However, a non-significant trend of an increased percentage of macrolide-resistant strains was observed.\n<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/sextrans-2019-054335","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T22:15:21Z","timestamp":1578003321000},"page":"396-398","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["<i>Mycoplasma genitalium<\/i>\nacquisition and macrolide resistance after initiation of HIV pre-exposure prophylaxis in men who have sex with men"],"prefix":"10.1136","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7125-7001","authenticated-orcid":false,"given":"Jens Tomas","family":"Van Praet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanne","family":"Steyaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefaan","family":"Vandecasteele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Van Den Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Mahieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"De Buyser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Grootaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Descheemaeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijke","family":"Reynders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"2024092304150704000_96.6.396.1","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1001\/jama.2019.2947","article-title":"Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection","volume":"321","author":"Traeger","year":"2019","journal-title":"JAMA"},{"key":"2024092304150704000_96.6.396.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.02.036"},{"key":"2024092304150704000_96.6.396.3","doi-asserted-by":"publisher","DOI":"10.1086\/343829"},{"key":"2024092304150704000_96.6.396.4","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2004.012062"},{"key":"2024092304150704000_96.6.396.5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix853"},{"key":"2024092304150704000_96.6.396.6","doi-asserted-by":"crossref","unstructured":"Li Y , Su X , Le W , et al . Mycoplasma genitalium in symptomatic male urethritis: macrolide use is associated with increased resistance. Clin Infect Dis 2019;24.doi:10.1093\/cid\/ciz294","DOI":"10.1093\/cid\/ciz294"},{"key":"2024092304150704000_96.6.396.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2019.03.007"},{"key":"2024092304150704000_96.6.396.8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv246"},{"key":"2024092304150704000_96.6.396.9","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2008.035535"},{"key":"2024092304150704000_96.6.396.10","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2019-054124"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2019-054335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T17:56:12Z","timestamp":1727114172000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2019-054335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,8,19]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/sextrans-2019-054335"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2019-054335","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"type":"print","value":"1368-4973"},{"type":"electronic","value":"1472-3263"}],"subject":[],"published":{"date-parts":[[2020,1,2]]}}}